JP2012503665A5 - - Google Patents

Download PDF

Info

Publication number
JP2012503665A5
JP2012503665A5 JP2011529177A JP2011529177A JP2012503665A5 JP 2012503665 A5 JP2012503665 A5 JP 2012503665A5 JP 2011529177 A JP2011529177 A JP 2011529177A JP 2011529177 A JP2011529177 A JP 2011529177A JP 2012503665 A5 JP2012503665 A5 JP 2012503665A5
Authority
JP
Japan
Prior art keywords
oral dosage
dosage form
solid oral
pharmaceutically acceptable
aliskiren
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011529177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012503665A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/057993 external-priority patent/WO2010036686A1/en
Publication of JP2012503665A publication Critical patent/JP2012503665A/ja
Publication of JP2012503665A5 publication Critical patent/JP2012503665A5/ja
Pending legal-status Critical Current

Links

JP2011529177A 2008-09-24 2009-09-23 アリスキレンを含むガレヌス製剤および溶融押出し造粒によるその調製方法 Pending JP2012503665A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9959508P 2008-09-24 2008-09-24
US61/099,595 2008-09-24
US16179909P 2009-03-20 2009-03-20
US61/161,799 2009-03-20
PCT/US2009/057993 WO2010036686A1 (en) 2008-09-24 2009-09-23 Galenical formulation comprising aliskiren and process for its preparation by melt extrusion granulation

Publications (2)

Publication Number Publication Date
JP2012503665A JP2012503665A (ja) 2012-02-09
JP2012503665A5 true JP2012503665A5 (enExample) 2012-11-08

Family

ID=41323516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011529177A Pending JP2012503665A (ja) 2008-09-24 2009-09-23 アリスキレンを含むガレヌス製剤および溶融押出し造粒によるその調製方法

Country Status (19)

Country Link
US (1) US20110177166A1 (enExample)
EP (1) EP2328562A1 (enExample)
JP (1) JP2012503665A (enExample)
KR (1) KR20110063684A (enExample)
CN (1) CN102164584A (enExample)
AR (1) AR073651A1 (enExample)
AU (1) AU2009296718A1 (enExample)
BR (1) BRPI0919077A2 (enExample)
CA (1) CA2736259A1 (enExample)
CL (1) CL2011000614A1 (enExample)
CO (1) CO6351712A2 (enExample)
EC (1) ECSP11010998A (enExample)
MA (1) MA32722B1 (enExample)
MX (1) MX2011003077A (enExample)
PE (1) PE20110925A1 (enExample)
RU (1) RU2011116122A (enExample)
TW (1) TW201016210A (enExample)
WO (1) WO2010036686A1 (enExample)
ZA (1) ZA201101686B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075880A1 (es) * 2009-03-20 2011-05-04 Novartis Ag Formulaciones galenicas de compuestos organicos que comprenden alisquireno y valsartan. uso. metodo.
EP2382967A1 (de) * 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
TWI657090B (zh) * 2013-03-01 2019-04-21 英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
FR3055800B1 (fr) * 2016-09-15 2020-06-26 Unither Pharmaceuticals Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules
CN114129569A (zh) * 2020-09-04 2022-03-04 上海医药集团股份有限公司 一种含氮的饱和杂环化合物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
AR050615A1 (es) * 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
PE20081157A1 (es) * 2006-11-07 2008-09-26 Novartis Ag Forma cristalina de hemifumarato de alisquireno
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
AR066168A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Formulaciones galenicas de compuestos organicos
WO2009040427A1 (en) * 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of organic compounds
EP2062874B1 (en) * 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren

Similar Documents

Publication Publication Date Title
BRPI0713785A2 (pt) formas de dosagem sólidas de valsartana, amlodipina e hidroclorotiazida e métodos de fabricação das mesmas
JP2012503665A5 (enExample)
AU2008309058B2 (en) Galenical formulations of Aliskiren and Valsartan
JP2009542709A5 (enExample)
CN1921840A (zh) 多层片剂
JP2003516341A5 (enExample)
WO2008116601A4 (en) Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
AU2008231626B2 (en) A tablet having improved stability with at least two actives
RU2011116122A (ru) Галеновая композиция, включающая алискирен и способ ее получения экструзионной грануляцией из расплава
CN102525879B (zh) 制备阿瑞匹坦固体分散组合物的方法
CN102525880B (zh) 一种阿瑞匹坦固体分散组合物
JP2009541239A5 (enExample)
AU2009292908B2 (en) Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine
KR101801476B1 (ko) 반복 고온용융 압출 성형된 약제학적 조성물의 제조 방법 및 이에 의해 제조된 약제학적 조성물
RU2010121824A (ru) Новая антиретровирусная комбинация
CN1714794A (zh) 厄贝沙坦氢氯噻嗪分散片及其制备方法
CN101234095B (zh) 一种定时释放制剂及其制备方法
Tewari et al. Extrusion: An Enabling Technology for Controlled-Release Hydrophilic Matrix Systems
JP7362302B2 (ja) レベチラセタムを含有する錠剤とその製造方法
RU2011142081A (ru) Галеновые фиксированные комбинации валсартана и алискирена
CN101062038A (zh) 坎地沙坦氢氯噻嗪分散片及其制备方法
RU2010116528A (ru) Галеновые композиции, содержащие алискирен и валсартан
HK1103011A (en) Multilayer tablet